A prospective cohort study of the effect of depot medroxyprogesterone acetate on detection of plasma and cervical HIV-1 in women initiating and continuing antiretroviral therapy.

@article{Day2014APC,
  title={A prospective cohort study of the effect of depot medroxyprogesterone acetate on detection of plasma and cervical HIV-1 in women initiating and continuing antiretroviral therapy.},
  author={Summer L. Day and Susan M Graham and Linnet N Masese and Barbra Ann Richardson and James N Kiarie and Walter G. Jaoko and Kishorchandra N. Mandaliya and Vrasha Chohan and Julie Overbaugh and R Scott McClelland},
  journal={Journal of acquired immune deficiency syndromes},
  year={2014},
  volume={66 4},
  pages={
          452-6
        }
}
Depot medroxyprogesterone acetate (DMPA) use among HIV-1-infected women may increase transmission by increasing plasma and genital HIV-1 RNA shedding. We investigated associations between DMPA use and HIV-1 RNA in plasma and cervical secretions. One hundred two women initiated antiretroviral therapy, contributing 925 follow-up visits over a median of 34 months. Compared with visits with no hormonal contraception exposure, DMPA exposure did not increase detection of plasma (adjusted odds ratio… CONTINUE READING
BETA